Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...
Stocktwits on MSN
Eli Lilly stock rises after late-stage data shows longer survival with breast cancer drug
The study showed benefits beyond survival, including slower disease progression in certain patient groups. ・Combining the ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...
Jan 22 (Reuters) - Eli Lilly and Co's stomach cancer drug ramucirumab met its primary goal of improving overall survival in a late stage-study, extending the lives of patients for more than a month ...
Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) HO Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, ...
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback